1. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321:129-135.
2. USPSTF. Final recommendation statement: Aspirin use to prevent cardiovascular disease and colorectal cancer: Preventive medication. https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/aspirin-to-prevent-cardiovascular-disease-and-cancer. Published 2016. Accessed September, 13 2018.
3. Gaziano JM, Brotons C, Coppolecchia R, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392:1036-1046.
4. ASCEND Study Collaborative Group. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018.
5. ASPREE. Scientific overview. Accessed September, 13 2018 at: https://aspree.org/usa/researchers/aspree-scientific-summary/.
6. De Berardis G, Sacco M, Evangelista V, et al. Aspirin and simvastatin combination for cardiovascular events prevention trial in diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials. 2007;8:21.
7. Chronotherapy with low-dose aspirin for primary prevention of cardiovascular events in subjects with impaired fasting glucose or diabetes (CARING study). Accessed September, 13 2018 at: https://clinicaltrials.gov/ct2/show/nct00725127?term=chronotherapy+with+low-dose+aspirin+for+primary+prevention+%28caring%29&rank=1